Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Marizomib for central nervous system-multiple myeloma. Br J Haematol 2017 04;177(2):221-225 PMID: 28387460

Pubmed ID

28387460

DOI

10.1111/bjh.14498

Abstract

Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifestation of extra-medullary disease with few therapeutic options, highlighting the unmet clinical need in these patients. Marizomib demonstrated encouraging activity in RRMM and has emerging clinical activity in glioma, making it a potential CNS-MM therapeutic intervention. Herein, we present two patients with RRMM and CNS involvement who benefited from marizomib-based therapy. These cases provide the first proof of principle for further exploring marizomib in CNS-MM patients.

Author List

Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P

Authors

Binod Dhakal MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-85017133877   13 Citations

MESH terms used to index this publication - Major topics in bold

Adult
Central Nervous System Neoplasms
Humans
Lactones
Male
Middle Aged
Multiple Myeloma
Pyrroles
jenkins-FCD Prod-332 f92a19b0ec5e8e1eff783fac390ec127e367c2b5